5 Stocks Dragging In The Health Services Industry

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 78 points (-0.5%) at 14,583 as of Wednesday, April 3, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 720 issues advancing vs. 2,193 declining with 115 unchanged.

The Health Services industry currently sits down 1.0% versus the S&P 500, which is down 0.7%. On the negative front, top decliners within the industry include Tenet Healthcare ( THC), down 5.9%, HCA Holdings ( HCA), down 4.7%, Health Management Associates ( HMA), down 4.0%, Community Health Systems ( CYH), down 4.1% and Universal Health Services ( UHS), down 2.4%. Top gainers within the industry include Intuitive Surgical ( ISRG), up 2.5%, St Jude Medical ( STJ), up 1.0%, Aetna ( AET), up 0.6% and Agilent Technologies ( A), up 0.6%.

TheStreet Ratings group would like to highlight 5 stocks pushing the industry lower today:

5. Mettler-Toledo International ( MTD) is one of the companies pushing the Health Services industry lower today. As of noon trading, Mettler-Toledo International is down $3.38 (-1.6%) to $208.20 on average volume Thus far, 107,001 shares of Mettler-Toledo International exchanged hands as compared to its average daily volume of 162,100 shares. The stock has ranged in price between $207.88-$211.80 after having opened the day at $211.80 as compared to the previous trading day's close of $211.58.

Mettler-Toledo International Inc. supplies precision instruments and services worldwide. The company operates in five segments: U.S. Operations, Swiss Operations, Western European Operations, Chinese Operations, and Other. Mettler-Toledo International has a market cap of $6.4 billion and is part of the health care sector. The company has a P/E ratio of 23.2, above the S&P 500 P/E ratio of 17.7. Shares are up 9.5% year to date as of the close of trading on Tuesday. Currently there are 4 analysts that rate Mettler-Toledo International a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Mettler-Toledo International as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, revenue growth, notable return on equity and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Mettler-Toledo International Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

4. As of noon trading, Zimmer Holdings ( ZMH) is down $0.82 (-1.1%) to $74.51 on light volume Thus far, 368,157 shares of Zimmer Holdings exchanged hands as compared to its average daily volume of 1.1 million shares. The stock has ranged in price between $74.30-$75.42 after having opened the day at $75.39 as compared to the previous trading day's close of $75.33.

Zimmer Holdings, Inc., through its subsidiaries, engages in the design, development, manufacture, and marketing of orthopedic reconstructive devices, spinal and trauma devices, biologics, dental implants, and related surgical products in the Americas, Europe, and the Asia Pacific. Zimmer Holdings has a market cap of $12.6 billion and is part of the health care sector. The company has a P/E ratio of 17.5, below the S&P 500 P/E ratio of 17.7. Shares are up 13.0% year to date as of the close of trading on Tuesday. Currently there are 12 analysts that rate Zimmer Holdings a buy, no analysts rate it a sell, and 15 rate it a hold.

TheStreet Ratings rates Zimmer Holdings as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, attractive valuation levels, solid stock price performance and growth in earnings per share. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Zimmer Holdings Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

3. As of noon trading, Stryker Corporation ( SYK) is down $0.52 (-0.8%) to $65.04 on average volume Thus far, 645,656 shares of Stryker Corporation exchanged hands as compared to its average daily volume of 1.7 million shares. The stock has ranged in price between $64.80-$65.64 after having opened the day at $65.62 as compared to the previous trading day's close of $65.56.

Stryker Corporation, a medical technology company, provides reconstructive, medical and surgical, and neurotechnology and spine products for doctors, hospitals, and other healthcare facilities. Stryker Corporation has a market cap of $24.6 billion and is part of the health care sector. The company has a P/E ratio of 19.3, above the S&P 500 P/E ratio of 17.7. Shares are up 19.6% year to date as of the close of trading on Tuesday. Currently there are 13 analysts that rate Stryker Corporation a buy, no analysts rate it a sell, and 12 rate it a hold.

TheStreet Ratings rates Stryker Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Stryker Corporation Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

2. As of noon trading, Boston Scientific ( BSX) is down $0.12 (-1.5%) to $7.77 on average volume Thus far, 10.0 million shares of Boston Scientific exchanged hands as compared to its average daily volume of 22.4 million shares. The stock has ranged in price between $7.74-$7.85 after having opened the day at $7.78 as compared to the previous trading day's close of $7.89.

Boston Scientific Corporation develops, manufactures, and markets medical devices used in various interventional medical specialties worldwide. Boston Scientific has a market cap of $10.5 billion and is part of the health care sector. Shares are up 37.7% year to date as of the close of trading on Tuesday. Currently there are 4 analysts that rate Boston Scientific a buy, no analysts rate it a sell, and 12 rate it a hold.

TheStreet Ratings rates Boston Scientific as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity and feeble growth in its earnings per share. Get the full Boston Scientific Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

1. As of noon trading, Baxter International ( BAX) is down $0.52 (-0.7%) to $71.69 on light volume Thus far, 943,246 shares of Baxter International exchanged hands as compared to its average daily volume of 2.9 million shares. The stock has ranged in price between $71.47-$72.33 after having opened the day at $72.21 as compared to the previous trading day's close of $72.21.

Baxter International Inc., through its subsidiaries, develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. Baxter International has a market cap of $39.3 billion and is part of the health care sector. The company has a P/E ratio of 17.3, below the S&P 500 P/E ratio of 17.7. Shares are up 8.3% year to date as of the close of trading on Tuesday. Currently there are 12 analysts that rate Baxter International a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Baxter International as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, increase in net income, revenue growth and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Baxter International Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

A reminder about TheStreet Ratings group: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

null

More from Markets

Stocks Rise as Bond Yields Inch Closer to 3% Threshold

Stocks Rise as Bond Yields Inch Closer to 3% Threshold

Akorn's Stock Crashes as Germany's Fresenius Ends Takeover Amid Data Allegations

Akorn's Stock Crashes as Germany's Fresenius Ends Takeover Amid Data Allegations

Trump to Blame for Oil's Recent Surge, Not OPEC

Trump to Blame for Oil's Recent Surge, Not OPEC

3 Things Investors Must Know for Monday

3 Things Investors Must Know for Monday

U.S. Earnings On Pace for Best Season in Two Decades but Tech Giants Await

U.S. Earnings On Pace for Best Season in Two Decades but Tech Giants Await